Antisense completes dosing in phase two ATL1102 trial


Antisense Therapeutics (ASX:ANP) has announced that dosing has been completed in all nine patients following six months of treatment in its ATL1102 phase two Duchenne muscular dystrophy (DMD) trial.

The company said results from the completion of dosing in all patients are anticipated to be reported before the end of the year.  

Upon completion of dosing, patients will continue to be monitored for an additional two month period.  

"Regulatory scientific advice meetings for further development of ATL1102 are currently in progress in Europe, with the final meeting taking place this week," said the company.

"The next step will be to seek advice from the European Medicines Agency (EMA) with the purpose of receiving the EMA’s acceptance of the overall development program for ATL1102 in DMD, in particular the Phase IIb clinical study and path for product registration in Europe."

“We are very pleased with how the Phase II DMD study has progressed having completed dosing on time and with no patient withdrawals or any reports of Serious Adverse Events," said CEO Mark Diamond.

"Preliminary safety and efficacy data is providing much confidence as we engage with key opinion leaders who are highly supportive of our future clinical planning and are actively involved with our regulatory interactions. We look forward to receiving the data on all patients post completion of their dosing and reporting on Phase IIb plans once appropriately firmed up.”